Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-8.46%
$1.68
0% positive prob.
5-Day Prediction
-10.03%
$1.66
0% positive prob.
20-Day Prediction
-34.02%
$1.21
0% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q4 2025 | SELL | -8.46% | -10.03% | -34.02% | 100.0% | Pending |
| Q3 2023 | SELL | -8.46% | -10.03% | -34.02% | 100.0% | +5.71% |
SEC 8-K filings with transcript text
Mar 6, 2026 · 100% conf.
1D
-8.46%
$1.68
Act: +1.63%
5D
-10.03%
$1.66
20D
-34.02%
$1.21
false 0001704287
0001704287
2026-03-06 2026-03-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 6, 2026
(Exact Name of Registrant as Specified in its Charter)
delaware 001-41031 47-3552922
(State or Other Jurisdiction of Incorporation or Organization) (Commission File No.) (I.R.S. Employer Identification No.)
360 Massachusetts Avenue, Suite 203
Acton,
(Address of principal executive offices and zip code)
(844) 327-7078
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol (s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
The Nasdaq Stock Market LLC
Item 2.02Results of Operations and Financial Condition.
On March 6, 2026, Bluejay Diagnostics, Inc. (the “Company”) issued a press release providing a corporate and strategic update, as well as certain financial results as of and for the year ended December 31, 2025. A copy of that press release is furnished with this report as Exhibit 99.1.
The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits
99.1
Press release, dated March 6, 2026
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
Bluejay Diagnostics, Inc.
By:
/s/ Neil Dey
Neil Dey
President and Chief Executive Officer
Date: March 6, 2026
Nov 9, 2023 · 100% conf.
1D
-8.46%
$23.07
Act: +5.71%
5D
-10.03%
$22.67
Act: +5.71%
20D
-34.02%
$16.63
false 0001704287
0001704287
2023-11-09 2023-11-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
8-K
OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 9, 2023
Bluejay Diagnostics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware
001-41031
47-3552922
(State or Other Jurisdiction of
Incorporation or Organization)
(Commission File No.)
(I.R.S. Employer
Identification No.)
360 Massachusetts Avenue, Suite 203
Acton,
(Address of principal executive offices and zip code)
(844) 327-7078
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol (s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
The NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 9, 2023, Bluejay Diagnostics, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2023 and a corporate update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
Exhibit No.
Description
99.1
Press release dated November 9, 2023
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
1
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Bluejay Diagnostics, Inc.
By: /s/ Neil Dey
Neil Dey
Chief Executive Officer
Dated: November 9, 2023
2
Aug 16, 2023
0001704287 false
0001704287
2023-08-16 2023-08-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
August 16, 2023
Bluejay Diagnostics, Inc.
(Exact Name of Registrant as Specified in its Charter)
delaware
001-41031
47-3552922
(State or Other Jurisdiction of
Incorporation or Organization)
(Commission File No.)
(I.R.S. Employer
Identification No.)
360 Massachusetts Avenue, Suite 203
Acton, MA 01720
(Address of principal executive offices and zip code)
(844) 327-7078
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol (s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
The NASDAQ Stock Market LLC
Item 2.02 Results of Operations and Financial Condition.
On August 16, 2023, Bluejay Diagnostics, Inc. (the “Company”) issued a press release announcing its financial results for the six months ended June 30, 2023 and a corporate update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
Exhibit No.
Description
99.1
Press release dated August 16, 2023
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
1
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Bluejay Diagnostics Inc.
By: /s/ Kenneth Fisher
Kenneth Fisher
Chief Financial Officer
Dated: August 16, 2023
2
This page provides Bluejay Diagnostics Inc. (BJDX) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on BJDX's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.